Trump Admin Blocks Federal Funds for Drug Test Strips, Alarming Harm Reduction Groups

The decision landed quietly but hit hard. In early August, officials in the Trump administration issued a directive that would reshape how federal money could be spent on one of the simplest, cheapest tools in overdose prevention: test strips that let drug users check whether their supply contains fentanyl or other lethal adulterants. Federal grants, they said, could no longer be used to distribute them.

The ruling sent shockwaves through addiction treatment organizations and public health groups across the country. For years, these strips had become a cornerstone of harm reduction work—the practical, unsexy business of keeping people alive while they struggle with addiction. A user could dip a strip into a dissolved sample of their drug and within minutes know whether fentanyl was present. It was not treatment. It was not recovery. It was simply information that could mean the difference between using safely and dying.

The strips cost pennies. They require no prescription, no clinical setting, no judgment. They work. Study after study has shown that access to drug checking tools reduces overdose risk and, critically, does not increase drug use. In a landscape where fentanyl has contaminated street supplies across nearly every American city, turning off federal funding for their distribution felt to many public health workers like stepping backward at precisely the moment when forward motion was most urgent.

Addiction organizations that had built distribution programs around these strips now faced a stark choice: find new funding sources or stop handing them out. Some groups had integrated strip distribution into syringe services, others into community outreach, still others into treatment intake. The strips were not the whole answer to the overdose crisis—nothing is—but they were a proven, accessible piece of it. And now that piece was being removed from the federal toolkit.

Public health experts warned immediately that the policy would likely cost lives. The fentanyl crisis had not paused. Overdose deaths remained near historic highs. Users were not going to stop using; they were simply going to lose one more tool for staying alive while they did. The strips represented a form of pragmatism that had slowly gained acceptance in public health over the past decade—the idea that you meet people where they are, that you reduce harm even when you cannot eliminate it, that you keep people breathing long enough for other interventions to become possible.

The timing seemed particularly pointed. The nation was in the midst of a fentanyl emergency that had killed tens of thousands annually. Harm reduction had moved from the margins into mainstream public health policy. Cities and states had invested in syringe services, naloxone distribution, supervised consumption sites. The strips fit naturally into this ecosystem. They were not controversial in public health circles; they were considered evidence-based practice.

But the new administration appeared to view them differently—perhaps as tacit endorsement of drug use, perhaps as a distraction from enforcement-focused approaches, perhaps simply as collateral damage in a broader reorientation of federal drug policy. Whatever the reasoning, the effect was immediate and concrete: organizations that had been distributing these strips with federal support would have to choose between finding alternative funding or discontinuing the service.

For the people who used those strips—people living with addiction in American cities, people trying to survive on contaminated streets—the choice had already been made for them. They would have fewer tools. The risk would be higher. The math was simple, and it was grim.